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Selective Cyclooxygenase-2 Inhibition Produces Heterogeneous
Erythema Response to Ultraviolet Irradiation
To the Editor:
The pattern of response to acute ultraviolet radiation (UVR)
injury is well described (Black et al, 1997). UVR causes
damage to DNA and other cellular components such as
proteins and lipids, initiating a repair response. Erythema,
increased keratinocyte proliferation, and induction of in-
flammatory cytokines and enzymes such as cyclooxygen-
ase-2 (COX-2) occur (Buckman et al, 1998; Nakamura
et al, 2000; Nickoloff et al, 2002; Wilgus et al, 2002). It is
clear that the changes produced by UV light are responsi-
ble for skin cancer. It is also certain that how these
responses are regulated collectively must dictate the re-
sistance of an individual to skin cancer (Marks and Furs-
tenberger, 2000).
Increased skin synthesis of prostaglandins (PG) is char-
acteristic of the acute UVR response. Production of PG
depends on two cyclooxygenase enzymes (COX-1 and
COX-2) (Funk, 2001). COX-1 is constitutively expressed,
whereas COX-2 is induced by mitogens, hormones, and
environmental stimuli. Increased COX-2 expression and el-
evated PGE2 are commonly observed in epithelial malig-
nancies. Recent work shows cyclooxygenase inhibitors are
potent chemopreventive agents in several malignancies,
particularly in colon cancer and UV-induced skin cancer in
mice (Furstenberger et al, 1989; Fischer et al, 1999; Pent-
land et al, 1999; An et al, 2002; Sales et al, 2002; Singh-
Ranger and Mokbel, 2002).
Despite the suggestive evidence that selective COX-2
inhibitors may impact the UVR response and skin cancer
risk, little direct evidence in humans is available. This study
examined whether the selective cyclooxygenase-2 inhibitor
celecoxib could affect UVR-induced erythema and prolifer-
ation. Our results indicate that in a subset of subjects, ery-
thema and proliferative cell nuclear antigen (PCNA) are
suppressed by celecoxib treatment. We propose this het-
erogeneity of response may underlie the capacity of
celecoxib to afford protection to some, but not all, individ-
uals with susceptibility to skin or other cancers.
Results and Discussion
All subjects developed a gradient of erythema responses 24
h after UVR exposure, so that a minimal erythema dose
(MED), two MED and three MED sites were identifiable.
The pre-treatment erythema response of subjects was
then compared with that obtained during treatment with
the selective COX-2 inhibitor celecoxib. The majority of
subjects had no change in the maximal intensity of their
erythema response, but a subset had a clear reduction (see
Fig 1). This change did not occur in placebo-treated sub-
jects. Erythema suppression did not correlate with skin
type, age, sex, other drug ingestion, or celecoxib serum
level.
Figure1
Erythema response during celecoxib treatment is heterogeneous.
Erythema produced 24 h after ultraviolet radiation (UVR) exposure was
measured using a chromometer (represented as a). Twelve sites were
exposed to graded doses of UVR in each individual. (A) Representative
erythema curves are shown. The left side of each frame is the erythema
curve before celecoxib treatment. The curve in the right side of each
frame was collected from the same individual after treatment with
celecoxib 200 mg b.i.d. (B) Erythema response before and after
celecoxib treatment in the 12 subjects studied in the second clinical
trial. Subjects whose erythema was not statistically different after
treatment are shown in black, whereas those in which erythema sup-
pression was statistically significant are shown in red (po0.05, paired t
test).
Abbreviations: COX-2, cyclooxygenase-2; MED, minimal erythema
dose; PCNA, proliferative cell nuclear antigen; UVR, ultraviolet
radiation
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To enlarge on this observation, suppression of erythema
by celecoxib treatment was studied in an additional 12
subjects. After baseline erythema responses were meas-
ured, all subjects received 200 mg celecoxib twice daily for
10 d before irradiation was repeated (Fig 2). In this second
group of subjects, erythema suppression was present in
50% of subjects. This group, termed ‘‘responders,’’ was
defined as those subjects in whom the pre-treatment versus
post-treatment erythema intensity in the four sites exposed
to the largest doses of UVR was statistically different
(po0.05) as assessed by a paired t test.
Immunohistochemical stains were done to assess UVR
induction of PCNA (Manne et al, 1998). A two MED expo-
sure induced PCNA in basal nuclear keratinocytes 96 h
post-irradiation, as previously reported (Einspahr et al,
1999). Initial statistical analysis of drug effects on PCNA
expression in all subjects taking celecoxib was performed
using a Wilcoxon’s signed-rank test of differences between
paired samples. No significant effect of drug treatment was
found at any of the doses tested. As the erythema data
clearly indicated that only a subset of subjects respond to
celecoxib treatment with erythema suppression, biopsy da-
ta from subjects in which treatment produced statistically
significant erythema reduction (as defined previously) were
selected for further analysis. Nine subjects in the first clin-
ical protocol met these criteria. This analysis revealed that
subjects demonstrating significant erythema suppression
because of drug treatment also had decreased PCNA stain-
ing (Table I). This change was not present in similarly treated
non-responders.
This heterogeneity of the erythema response in humans
is in contrast to work done in mice (Furstenberger et al,
1989; Fischer et al, 1999; Pentland et al, 1999), where a
consistent effect of drug on proliferation in all treated an-
imals is observed. The difference may be attributable to the
genetic homogeneity of inbred mouse strains, compared
with the heterogeneity of human populations. Heterogeneity
in the erythema response after celebrex administration is
also distinct from the erythema effects of the non-selective
COX inhibitor indomethacin, which suppresses UVR ery-
thema in 100% of human subjects taking drug (Farr and
Diffey, 1986; Dobrev, 2001). The data presented here indi-
cate that only 50% of subjects have an erythema response
that is significantly regulated through COX-2-dependent
mechanisms.
Recent work by this group and others suggest the pos-
sibility that this difference in erythema response may be
extrapolated to skin cancer susceptibility. Treatment with
selective COX-2 inhibitors has been shown to be beneficial
in many animal models and human epithelial cancers—co-
lon, cervix, and breast (Marks and Furstenberger, 2000;
Sales et al, 2001; Singh-Ranger and Mokbel, 2002). For
example, the incidence of tumors is greatly reduced when
COX-2 is deleted in mice genetically predisposed to colon
cancer (Chulada et al, 2000) or subjected to chemical car-
cinogenesis of the skin (Tiano et al, 2002). Treatment with
celecoxib also protects SKH mice from photocarcinogen-
esis (Fischer et al, 1999; Pentland et al, 1999). Human
studies have also shown celecoxib can provide protection
in colon and prostate cancer studies. As celecoxib was only
capable of inhibiting expression of the proliferative marker
PCNA in the responder group, one can speculate that only
individuals in which the erythema response or proliferative
markers are inhibited by a prospective chemopreventive
drug are likely to derive benefit from long-term treatment to
prevent photocarcinogenesis.
It is of considerable interest to determine whether COX-2
inhibitors can serve as chemopreventive agents in humans
at increased risk from actinic keratoses or non-melanoma
skin cancer. As squamous cell carcinoma of the skin is a
very common tumor (Bruce and Brodland, 2000), the ca-
pacity to prevent morbidity through this relatively non-toxic
form of chemoprevention carries substantial benefit. But it
is also necessary to consider risks of treatment and cost of
Figure 2
Timeline of procedures for clinical studies. After obtaining informed
consent, experimental procedures for the first clinical protocol were
conducted as shown in the upper timeline (study #1). The procedures
followed for the second clinical study are shown in the lower timeline
(study #2). MED, minimal erythema dose.
Table I. Comparison of pre-treatment versus post-treatment PCNA
Mean  SEM
p-value
Pre-treatment Post-treatment
Control 2 MED Control 2 MED
Basal nucleus
Responders 0.145  0.03 0.84  0.15 0.24  0.07 0.58  0.14 0.004
Non-responders 0.28  0.06 0.92  0.08 0.25  0.06 0.88  0.09 0.872
p-value based on Wilcoxon’s signed-rank test for paired comparisons.
PCNA, proliferative cell nuclear antigen; MED, minimal erythema dose.
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population wide drug administration in a disease as com-
mon as squamous cell carcinoma. Recent observations that
some COX-2 selective inhibitors increase the risk of stroke
and heart attacks underline this need (Urquhart, 2005).
Thus, identification of a subset of individuals who might be
more likely to benefit from selective COX-2 inhibitors will be
beneficial.
Methods
Institutional approval for the experiments were obtained, and patient
consent and protocols were adherent to the Helsinki Guidelines. In the
initial phase of the study, 45 subjects were enrolled in a double-blinded,
placebo-controlled, randomized study to examine the effects of
celecoxib on UVR erythema and the biomarker of proliferation, PCNA
(see Fig 2). Subjects with skin types I–III were included (Fitzpatrick,
1988). At baseline, subjects received UV irradiation to the buttock using
a 1000W Xenon arc lamp solar simulator (Model X PS 200, Solar Light
Co., Philadelphia, Pennsylvania). The lamp is filtered to produce a
spectrum of light virtually identical to sunlight through the near visible
range. UVR was measured using an IL1700 meter with an SED 400
probe to determine irradiance in the UVA/UVB range (International
Light, Newburyport, Massachusetts). Twelve doses of UVR (290–400
nm) were administered in increments increasing 25% per irradiation site
from 20 to 290 mJ per cm2. Twenty-four hours post-irradiation, ery-
thema readings were obtained using a Minolta chromameter (Minolta,
Tokyo, Japan). The smallest dose of light resulting in perceptable ery-
thema by clinical observation was designated the MED. The chroma-
meter a readings at 24 h post-irradiation were used to generate an
erythema curve of UV dose versus erythema intensity. At 96 h post-UV
irradiation, two biopsies were obtained from each subject, one from the
two MED site and a second from 3 cm distant unirradiated skin.
Subjects then received medication to be taken orally for one of the
following 14-d treatment regimens: (1) placebo, (2) 100 mg celecoxib
twice daily, (3) 200 mg celecoxib twice daily, (4) 200 mg celecoxib daily,
or (5) 400 mg celecoxib daily. After 10 d of drug or placebo treatment,
irradiation was repeated and measures of erythema and biopsies were
obtained as before.
Standard immunostaining procedures were used to determine
the expression of PCNA as previously described (mouse monoclonal;
clone PC10; Santa Cruz, Santa Cruz, California; .03 mg per mL) (Manne
et al, 1998). Assessment of the staining was determined by two obser-
vers blinded to treatment assignment (Krontiras et al, 1999). Immuno-
staining intensity was scored 0 (no staining) to 4 (highest intensity
staining).
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